Founded by Hsih-Te Yang, PhD, currently a principle investigator or assistant professor of the laboratory of intelligent systems medicine, Institute of Medical Informatics, Department of Computer Science and Information Engineering, National Cheng Kung Univeristy, Taiwan. i-Ab brings together a group of researchers with backgrounds in medicine, engineeering and information science, with the aim of revolutionizing biologics discovery toward regulatory approval.
Conventionally, the brand new antibody leads were discovered by two or more screening cycles with bunch of materials and time. i-Ab's approaches (In-silico screening, ISS) will revolutionize the conventional processes of biologics discovery and development by increasing R&D productivity as well as reducing attrition rates of therapeutic antibodies against most diseases, such as cancers, metabolic disorders, infections and neuron degenerations. The target customers are big pharma, biotech or stakeholders. We help them to control the cost and facilitate the total product life cycle toward regulatory approval using our core technologies. Namely, our services and products shall enable R&D groups in identifying drug candidates with a higher probability of success.
Phage antibody library construction
Initialization: planning for the library size
A computational technology platform was successfully established for high-throughput antibody screening (iHT-AbTM), which incorporates two databases (i-TargetDBTM and i-AbDBTM) as value-added big biomedical data sources. i-Ab provides professional services in contrast with those experiments of conventional platform.
Screening antibody (i-Ab001, i-Ab002, …) candidates by Preclinical Efficacy and Safety Index (PESI): a perspective analysis of clinical trial
i-Ab has not received any reviews.
i-Ab has not received any endorsements.